Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
Maurizio Scaltriti(Memorial Sloan Kettering Cancer Center), José Baselga(Universitat Autònoma de Barcelona)
Cited by 876
Related Papers
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
|Journal of Clinical Oncology|2005|409
Targeted therapies for breast cancer
|Journal of Clinical Investigation|2011|371
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
|Clinical Cancer Research|2004|277
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
|Cancer Cell|2016|228
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
|Molecular Cancer Therapeutics|2011|52